Anupam Rama
JPMorgan Chase & Co, Analysis Division
Welcome, everybody, to the forty fourth Annual JPMorgan Healthcare Convention. My title is Anupam Rama. I’m one of many senior biotech analysts right here at JPMorgan.
I am joined by my squad, Rati Pinge, Priyanka Grover, Joyce Zhou. Our subsequent presenting firm is Stable Biosciences. And presenting on behalf of the corporate, we’ve CEO, Bo Cumbo.
Alexander Cumbo
President, CEO & Director
Sure. Thanks, Anupam. Thanks JPMorgan for the invitation. It is good to see all of the pleasant faces within the viewers right now and people who are attending. Earlier than I begin, the forward-looking statements, I am going to provide you with — I’ll pause on the forward-looking statements and inform you slightly story.
Earlier than we really began the presentation, 2 of our attorneys come as much as me and speak about, are you enthusiastic about JPMorgan?
And I am like, “Oh, nice. What are you going to say?” Nicely, I’ll inform you about every thing that is happening. We have dosed 33 sufferers, all protected, no drug-induced liver harm, no myocarditis, no aHUS.
We have already enrolled our first affected person and scheduled our first affected person within the double-blind, placebo managed. We dosed our first affected person in FA. This has been — that is the most effective yr that we have ever had as an organization.
Our capsids — we have had 50 totally different agreements for our capsids. Individuals are beginning to come to us as a platform know-how firm and utilizing all our supply autos inside for a Stable inside for next-generation therapies.
We’ve got
